Responses
Regular and Young Investigator Award Abstracts
Checkpoint Blockade Therapy
491 Preclinical pharmacology modeling of HX009, a clinical stage first-in-class PD-1xCD47 BsAb, for anti-lymphoma applications
Compose a Response to This Article
Other responses
No responses have been published for this article.